Jack A. Khattar - 10 Sep 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
10 Sep 2025
Net transactions value
$0
Form type
4
Filing time
12 Sep 2025, 16:05:53 UTC
Previous filing
09 Sep 2025
Next filing
23 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Khattar Jack A. President, CEO, Director C/O SUPERNUS PHARMACEUTICALS INC., 9715 KEY WEST AVENUE, ROCKVILLE /s/ Timothy C. Dec, as attorney-in-fact 12 Sep 2025 0001539937

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SUPN Common Stock 1,111,983 10 Sep 2025 Direct
holding SUPN Common Stock 1,005,600 10 Sep 2025 By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Performance Share Unit Award $0 +20,000 $0.000000 20,000 10 Sep 2025 Common Stock 20,000 $0.000000 Direct F1
transaction SUPN Performance Share Units Award $0 +19,320 $0.000000 19,320 10 Sep 2025 Common Stock 19,320 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on April 30, 2021.
F2 On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.